-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 IEAkSn3LBWhJlkefVEqjYpBLWcWBKVntLuO6yUH/TuzoLpfuenxDkISaROuC1Gi6
 XcIjqb5LY3Mw+rDryrDCNg==

<SEC-DOCUMENT>0001129928-09-000017.txt : 20090407
<SEC-HEADER>0001129928-09-000017.hdr.sgml : 20090407
<ACCEPTANCE-DATETIME>20090407122638
ACCESSION NUMBER:		0001129928-09-000017
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20090407
FILED AS OF DATE:		20090407
DATE AS OF CHANGE:		20090407

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		09736931

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form-6k.htm
<DESCRIPTION>FORM 6K
<TEXT>
<html>
  <head>
    <title>form-6k.htm</title>
<!-- Licensed to: Oncolytics Biotech Inc.-->
<!-- Document Created using EDGARizer 4.0.7.0 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <div>&#160;</div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div>&#160;</div>
    <div><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECURITIES
AND EXCHANGE COMMISSION</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Washington,
D.C. 20549</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">Form
6-K</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Report
of Foreign Private Issuer</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to Rule&#160;13a-16 or 15d-16</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of
the Securities Exchange Act of 1934</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the
month of&#160;April 2009</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
File Number 000-31062</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">Oncolytics
Biotech Inc.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">(Translation
of registrant&#8217;s name into English)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Suite&#160;210,
1167 Kensington Crescent NW</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Calgary,
Alberta, Canada T2N 1X7</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">(Address
of principal executive offices)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark whether the registrant files or will file annual reports under
cover Form&#160;20-F or Form&#160;40-F.</font></div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr>
              <td valign="top" width="38%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form&#160;20-F&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#254;</font></font></div>
              </td>
              <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="38%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form&#160;40-F&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form&#160;6-K in paper as
permitted by Regulation&#160;S-T Rule&#160;101(b)(1):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T
Rule&#160;101(b)(1) only permits the submission in paper of a Form&#160;6-K if
submitted solely to provide an attached annual report to security
holders.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form&#160;6-K in paper as
permitted by Regulation&#160;S-T Rule&#160;101(b)(7):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T
Rule&#160;101(b)(7) only permits the submission in paper of a Form&#160;6-K if
submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction
in which the registrant is incorporated, domiciled or legally organized (the
registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on
which the registrant&#8217;s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been
distributed to the registrant&#8217;s security holders, and, if discussing a material
event, has already been the subject of a Form&#160;6-K submission or other
Commission filing on EDGAR.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark whether by furnishing the information contained in this Form, the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr>
              <td valign="top" width="38%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Yes&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
              </td>
              <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="38%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">No&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#254;</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If &#8220;Yes&#8221;
is marked, indicate below the file number assigned to the registrant in
connection with Rule&#160;12g3-2(b):&#160;&#160;&#160;82&#160;-&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td valign="bottom" width="7%" style="BORDER-BOTTOM: black 4px double">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">EXHIBIT</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NUMBER</font></div>
              </td>
              <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="bottom" width="69%" style="BORDER-BOTTOM: black 4px double">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">DESCRIPTION</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="top" width="69%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr>
              <td valign="top" width="7%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99.1</font></div>
              </td>
              <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="top" width="69%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">News
      Release Dated April 7, 2009 -&#160;Oncolytics Biotech&#174; Inc. Announces
      Positive Results of U.K. Phase II REOLYSIN&#174; and Radiation Combination
      Clinical Trial</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SIGNATURES</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="bottom" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr>
              <td align="left" valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" colspan="3" valign="top" width="39%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Oncolytics
      Biotech Inc.</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Registrant)</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="middle" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="middle" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="middle" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr>
              <td align="left" valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="top" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr>
              <td align="left" valign="middle" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="middle" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="middle" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr>
              <td align="left" valign="top" width="38%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date:&#160;&#160;April
      7, 2009</font></div>
              </td>
              <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="top" width="2%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
              </td>
              <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="top" width="36%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/&#160;&#160;Brad
      Thompson</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Brad
      Thompson</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief
      Executive Officer</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><br></div>
  </body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html>
  <head>
    <title>ex991.htm</title>
<!-- Licensed to: Oncolytics Biotech Inc.-->
<!-- Document Created using EDGARizer 4.0.7.0 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <div><img src="ex9910.jpg" alt=""><br>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">210, 1167
Kensington Cr. N.W</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Calgary,
Alberta</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Canada
T2N 1X7</font><br></div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;F</font><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">OR
IMMEDIATE RELEASE</font><br></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Oncolytics Biotech</font>&#174;<font style="DISPLAY: inline; FONT-WEIGHT: bold"> Inc. </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Announces Positive Results
of</font></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">U.K.</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"> Phase II REOLYSIN</font>&#174;<font style="DISPLAY: inline; FONT-WEIGHT: bold"> and Radiation Combination Clinical
Trial</font></font></div><br>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><br>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">CALGARY, AB, --- </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">April 7</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">, 200</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">9</font> - Oncolytics Biotech Inc.
(&#8220;Oncolytics&#8221;) (TSX:ONC, NASDAQ:ONCY) today announced positive results in
its&#160;U.K. Phase II clinical trial to evaluate the objective tumour response
rate of REOLYSIN&#174; in combination with low-dose radiation in patients with
advanced cancers.</font></div>
          <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A total
of 16 heavily pretreated patients with advanced cancer (melanoma (5), colorectal
(4), gastric (1), pancreas (1), ovarian (1), lung (1), cholangiocarcinoma (1)
sinus (1), and thyroid (1)) were enrolled in the trial.&#160;&#160;Most patients
had received prior chemotherapy (13 patients) or radiation (5 patients). Of 14
patients evaluable for response, 13 patients had stable disease (SD) or better
in the treated target lesions.&#160;&#160;Of these, partial responses (PR) were
observed in four patients (lung, melanoma (2) and gastric) and minor responses
were observed in two patients (thyroid, ovarian), for a total disease control
rate (stable disease + partial response + complete response) of 93% in the
treated lesions.&#160;&#160;The combination was well tolerated, with only mild
(Grade 1 or 2) toxicities noted.</font></div>
          <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;This is
a very high disease control rate in patients who have undergone prior
therapies,&#8221; said Dr. Brad Thompson, President and CEO of Oncolytics. &#8220;This
combination resulted in marked responses or stabilization in the treated target
lesions for most of the patients. These results are expected to allow us to
pursue REOLYSIN in combination with radical radiotherapy in future clinical
trials.&#8221;</font></div>
          <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The trial
(REO 008) was an open-label, single-arm, multi-centre Phase II study of REOLYSIN
delivered via intratumoural injection to patients during treatment with low-dose
fractionated radiotherapy.&#160;&#160;20 Gy of radiation was given in five
consecutive daily 4 Gy fractions combined with two intratumoural injections of
REOLYSIN (1x10(10) TCID(50)) on days two and four. The primary endpoint was
objective tumour response rate in treated lesions. Secondary endpoints were to
evaluate viral replication, immune response, and safety. Eligible patients
included those diagnosed with advanced or metastatic cancers that are refractory
(have not responded) to standard therapy or for which no curative standard
therapy exists.&#160;&#160;The Phase II trial followed a successful Phase Ia/Ib
combination REOLYSIN/radiation trial in which local and systemic responses were
noted.</font></div>
          <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Principal Investigator for the trial is Dr. Kevin Harrington of the Targeted
Therapy Laboratory, Cancer Research UK Centre for Cell and Molecular Biology at
The Institute of Cancer Research and Honorary Consultant in Clinical Oncology at
The Royal Marsden NHS Foundation Trust.</font><br></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">About
Oncolytics Biotech Inc.</font></div>
          <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Oncolytics
is a Calgary-based biotechnology company focused on the development of oncolytic
viruses as potential cancer therapeutics.&#160;&#160;Oncolytics&#8217; clinical
program includes a variety of Phase I/II and Phase II&#160;&#160;human trials
using REOLYSIN, its proprietary formulation of the human reovirus, alone and in
combination with radiation or chemotherapy.&#160;&#160;For further information
about Oncolytics, please visit <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.oncolyticsbiotech.com</font></font></div>
          <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">This
press release contains forward-looking statements, within the meaning of Section
21E of the Securities Exchange Act of 1934, as amended. Forward-looking
statements, including the Company&#8217;s expectations related to the U.K. Phase II
combination REOLYSIN/radiation clinical trial, and the Company&#8217;s belief as to
the potential of REOLYSIN as a cancer therapeutic, involve known and unknown
risks and uncertainties, which could cause the Company&#8217;s actual results to
differ materially from those in the forward-looking statements. Such risks and
uncertainties include, among others, the availability of funds and resources to
pursue research and development projects, the efficacy of REOLYSIN as a cancer
treatment, the tolerability of REOLYSIN outside a controlled test, the success
and timely completion of clinical studies and trials, the Company&#8217;s ability to
successfully commercialize REOLYSIN, uncertainties related to the research and
development of pharmaceuticals and uncertainties related to the regulatory
process. Investors should consult the Company&#8217;s quarterly and annual filings
with the Canadian and U.S. securities commissions for additional information on
risks and uncertainties relating to the forward looking statements. Investors
are cautioned against placing undue reliance on forward-looking statements. The
Company does not undertake to update these forward-looking statements, except as
required by applicable law.</font></div>
          <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FOR
FURTHER INFORMATION PLEASE CONTACT:</font></div>
          <div>
            <table cellpadding="0" cellspacing="0" width="100%">
                <tr>
                  <td align="left" valign="top" width="25%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Oncolytics
      Biotech Inc.</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cathy
      Ward</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">210,
      1167 Kensington Cr NW</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Calgary,
      Alberta T2N 1X7</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Tel:
      403.670.7377</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fax:
      403.283.0858</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">cathy.ward@oncolytics.ca</font></font></div>
                    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
                  </td>
                  <td align="left" valign="top" width="26%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The
      Equicom Group</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nick
      Hurst</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">325-300
      5th Ave. SW</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Calgary,
      AB, T2P 3C4</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Tel:
      403.538.4845</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fax:
      403.266.2453</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">nhurst</font><font style="DISPLAY: inline">@equicomgroup.com</font></font></div>
                    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
                  </td>
                  <td align="left" valign="top" width="28%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The
      Investor Relations Group</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Damian
      McIntosh</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11
      Stone St, 3rd Floor</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">New
      York, NY&#160;&#160;10004</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Tel:&#160;&#160;212.825.3210</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fax:&#160;&#160;212.825.3229</font></div>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">dmcintosh@investorrelationsgroup.com</font></font></div>
                  </td>
                </tr>
            </table>
          </div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-30-</font></div><br></div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      </div>
    </div>
  </body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex9910.jpg
<TEXT>
begin 644 ex9910.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````@```#$!`@`0````3@``````
M``!@`````0```&`````!````4&%I;G0N3D54('8T+C`P`/_;`$,``@$!`0$!
M`@$!`0("`@("!`,"`@("!00$`P0&!08&!@4&!@8'"0@&!PD'!@8("P@)"@H*
M"@H&"`L,"PH,"0H*"O_;`$,!`@("`@("!0,#!0H'!@<*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"O_``!$(`%$!
M4P,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/W\HHK+\9^,_#'P]\,WOC/QIKUII>E:;;M/?ZA>S!(H8QU8D_RZ
MDD`<FDW8#1>9%&<YK$\;?%#X>?#73UU7XA^.-(T.V9E5;C5M2BMD))P!F1@.
M37P+\:?^"G/[0W[1OQ-N/@3_`,$__!$T\9D:-/$XM`]Q<(,!ID$H$5K%UP\F
M21@C:>"SX>?\$8/B-\4-03QQ^UU^T'?7.H7`,EW9Z7.UW<JS;\J;JXW*"/E/
MRH1G(R?O'SY8V567+AX<WGLC14[?$['U(W_!3']A)',;_M'Z)D$CB&<^W_/*
MMKP/^W=^Q[\2=4_L;P?^T)X:N+HNB)#/>_9C(SMM54\X)O8GC:N37E=C_P`$
M8?V'X+&&WN_#WB"YECB59+F3Q).K2D#EB$(4$GG``'/`K#^)7_!$;]E#Q+H@
MM_`.K^(O#%\F[9=KJ!O8WR`,/'-U`Y^ZRGGJ>E+GS)?9C][$U2?<^QK+4;+4
M;=;NRNHY8G&4EB<,K#V(X/X5,&5NAS7Y7^._V;_V\?\`@F/K'_"R?@MX^N?$
MO@NWD#7B6B2/;I"'7"7=FQ(13N(\R(Y&6.Y,\_5O[#'_``4T^&/[5\4/@CQ+
M!%X=\<%';^Q'D9H;U4QF2VD(`8X.3&?G`4G!`W5I2QT)5/9U$XR\^OH$J;2N
MM3ZDHI$;<H;'44M=Q`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`#96`4[B`,<DG
MI7Y@_M:?&+XG_P#!33]I>#]D?]GV5[;POH%Y-_:-_+=8M[HQ2*DE]*JGF*,\
M1)R69\XR1M^N/^"FW[0NH?L\?LG:WKGAV]^SZUKCKHVCR@L&CDG!#R*5'#)$
M)&!XY4<UQO\`P1[_`&;[#X1_LPV_Q-U&TQK?CHK?SRNF&CLURMO&/]DKF7/\
M7F@GH,>9BF\366'CMO+T[&L;07,>W_LQ_LM_"O\`93^'<?P_^&&CK&)2)=4U
M&7+7%_/C!ED<DGV5<[5'`KTN@#`Q17HPA&G%1BK)&3;;NPHHHJ@&RQ+,A1L8
M(P01G-?GY_P4R_X)X>'_``GX:D_:E_9>T"70M<T*[6^UJPT-FC!A7&;JWC08
MBDC/[QBN`5#,1D<_H+4-_9VM_;/97MO'-#*C)+#*@974C!4@]00<8KGQ-"%>
M'*]^C[#BW%W1\W_\$U/VT%_:U^#[6_BIBOBWPRD-KX@+%!]MW*?+O$"@`*^&
MR,8#!ATQ7TM7Y8^,O!K_`/!-O_@IYX=U#P1.T/A'Q;<QLEDA5MMC=S>3-;E`
M5P(Y@&3H`%09.&!_4N)MV>.AK#`5IU(.G/XHNS*J12=UU'T445WD!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110!^='_!=?6)[_6?A;\-I(D6TNYK^Y>=`?,5MUO#@=L8D
M)Z=0.W%?H'X+\-:=X,\):;X3TE0+;3;"&U@^15^1$"CA0`.!V`%?GQ_P70T^
M_L/&?PJ\;7-MMTVW-]!-<!P=K^9;R8V_>/RHQX';'7`/Z'^'M6LM=T2TUK39
M2]M=VT<UO(5(W(RAE.#R.#TKS<,D\=6;\OR-)_!$N4445Z1F%%%%`!1110!\
M`?\`!>;PAHTGPQ\">/6@(U*#7Y]/CF7`_<20-*RGC)PT*D<\9;^\:^SOV>]:
MU3Q+\"_!OB37+QKB\O\`PIIT]W,R@&21[:-F;"@`9)/0"OCS_@O%K&FQ_!?P
M-H4EX@O)O%4MQ%;[OF>*.UD1W`[A6DC!]W%?7G[-D%U8?L]^!;"^M)(9H?!V
MF)+#,A1T86T8*LI&5((Y!KSZ7^_U?1?J5_R[B>/?\%1?VG_BO^RG\$M%\>?"
M*YT^'4+_`,41V$[ZC9>>GDM;SR$!<C!W1KSZ9KSO]A__`(*;>)?&_CH?`?\`
M:XMK#1?$VH>5/X;UFVB$%GJ4<R"2&,\E075E:.0$K(&`X;&Y_P#P78_Y-?\`
M"_\`V/</_I'=U0\??\$]O"W[7/[$?PT\8^$#;Z1X]TKX>Z6-+U/[B7R+:H5M
MK@CMG[DG5">ZY%85GB?KDG3=[+;OY%+E<+,^COVU?B1\2?A#^S'XL^*'PJU2
MPM=9T'3Q>Q2ZE:>=$T:2*9$V9&69-P!)X)%<K_P32_:(^)G[3_[-Q^)WQ9N[
M&;53K]W9[M/LO(C\J,1E?ER><L>:^-[#]NGX@77[+'Q-_8M_:LL+VT\::7X8
MN[72-2U'B6Z\I0WV:<L?FE"+E)`2)1CDG!;Z0_X(F+N_8I7G_F;=0_E%54L5
M[?%QY6[6=UYI@X*$+-'U9XD\3:#X-T2\\2^*-5M['3["V>>]O+J4)%#&HRS,
MQX``%?'%E^W?^T[^V#XQU#P=^P1\-M+M-$T>ZV:CX]\9,WD-AAA4A494NOS*
M#N8C.1'C->D_\%6?"7CWQK^Q3XJTCX?12S30M:W6HV=O;&62YLXIU>5%`!/&
M!(2.<1FO-/\`@B/\0?AE=?LX7GPYT76XE\3VNNW5[K&F3WBF:2-_+6.X2,<K
M$5")G^^K'/(K2M4F\4J*?*FK_P##,2BE&YW-U\-_^"K-B9]3M/VC/A=>R^4#
M%I\GA*>.)V7<0H;<2F[(!8[L``@<'/MWP/E^.-QX,2Z_:!M_#,.OR3.9+;PI
MY[6L,><*N^9BTC'DDX4#.`.,GKXQO7=TIP^0_6NJE14'>[^;N2W<\[_:;_:6
M^&O[+'PRN?B9\2M2*1(/+T[3X2#<:C<D96")3U8X))/"J"QX%?/7PA^,W_!2
M;]KG0[?XL_"ZQ\"?#7PC>V^='BU^VEU*YOL-@R?*4*J2&P2JY&"`00QY'_@N
MWX$\7:O\+O!?CG2I+V32-)UBXAU6W@@+0PO-&HBN)&!PI!4Q@D=9>"#@'Z3_
M`&!/B%X-^)7[(_@;6O!-O;6UM:>'X+"YL+5N+2X@01RQ$8&#N4GIR&!&003Q
M.I.KC94Y-I)77G_PQ25J:9YSXMTS_@K#\/-&D\6Z7X\^&?C>2SP[>&;?0)K.
M6\4Y!"2M*`"N0V,C=MP#G`.C^Q)_P4H^'W[6VMS?#G5/"=YX8\8VEF\T^DW,
MHE@N%0JLGDR<$E2>490P`SR`<?2MPVU\GIC)/I7Y/_L?6[?$+_@KIJ7B?X5W
M$MMI$7B;6[^XF@F:9)K0^:KDR*H&R61PRAOE^95YXI5IU,/5IQA)M2=K/4<4
MI)M]#]948.NX5\9_\$ZOVT_CM^TM^T)\1?AU\4M0TJ33/#4<ITM+#3!"Z[;Q
MX1N;<=WR@?CS7V7&/EW>M?FW_P`$;3C]L#XR?]<I_P#TY25OB9SCB:23T;=_
M/0E6Y6?I-5+Q%9:MJ&AW=EH6LC3[V6W=;6^-LLWD2$':^QL!\'!VDC/2KC-M
M[4,NX8KN)/@.V_X*(_M-_LK?M+O\'_V\=*TR;PY>X&G>)-`TEH8Q&7PMVF&;
MS8N0)$^_'R<''S?9OCOXX_"OX;_"JX^-/BWQG90>&H;);I=42821SQL`4\K;
MGS"^0%"Y+$@"L']J;]EGX8_M6_#.;X=?$>R*E=TNE:K;HOVC3;C&!-$Q_(J>
M&'![8_,?]EK]G'QM^T5^T;+^P[\4OC%J,W@OX;:EJ5W+I]M*PCG\BY2WD6$$
MGRO,9N"<^6K/M`+9KR*E3$X6?);FYOA?9^?D7925UT/K;]DW]J7]LC]M7XQW
M_CGP7IFF^$O@_IM_Y:37^D^=>W^P_P"ICD+X,C=78`I$#M&YA7TQ\==(^.VN
M^"TLOV??&6A:%KPO8V:]\0::]W;F`!MZ;$8'<25(.>Q]:Z/P3X)\+?#KPM8>
M"?!.B6VFZ3IELMO86-I$$CAC4<``?J>I/)R:U:[J5&:IVG)MO5_\#R);UN?%
MO[27B_\`X*:?LS?!C6?C7X@^.WPWU.ST983-96?@^999/,FCB&TM)@8,F>?2
MH/V7?'__``4R_:E^#6F_&GPS\<_AOI5GJ4UQ''97_@Z5Y4,4[Q$DK)CDH2,=
MC7IW_!5[_DPSQW_USL/_`$OMZSO^"0W_`"85X3/_`$_ZI_Z7SUR<C6-]GS.W
M+?<O[%SUW]GSP]^T-X>\-7L?[1_Q!T+Q!JTMYNLY?#VE-:00VX484AB69]VX
MD].F*\L_X*>_M+?%3]E?X"Z=\1/A'<V$.I7/B>WL)6U&R^T1F%X9W.%R.<QK
MS7TBJ[>]?&'_``7*;/[)6BG_`*GJT_\`26[K7%RE2P<G%ZI$P^(]Q_87^+_C
M7X]_LL>%/BY\1+BUEUG68+A[U[.V\J(E+J:-=J9./E1>_:MS]I7]I#X:?LM_
M#2[^*/Q-U4Q6T)\NRL8<&XO[@J2L$2D_,QP>>B@$D@"O/?\`@E;_`,F&^`/^
MO6\_]+KBO!_^"[O@OXA:Q\-O!?C#0K:YF\/Z1J5TNL^3N9()Y4C6":10,!<"
M5`Q(P9`!]ZI=:=/+_:+5V!1]ZQU'PS_:1_X*+?MCK!XT^`GPZ\+_``Y\&NQ^
MS:MXQ22]EU)"6Q)&B!=RC:!P`,MP[XP.\/A;_@JOX8/]KP?$_P"$WBAE^7^R
M+K1;NQ1\\;_.1F((ZXQSBNU_8*\5?#;Q5^R9X'E^%MY$^GV/ARULYK=9MSVU
MQ'&%FBD&YBK"0/D$]Z]DJZ-'VM)2<V[]GH'-9V,GP/'XRC\+6(^(4^G2:U]F
M4ZDVDQNEMYI&6$0D9FVCH"QR<9XS@?*7[;/_``4D\8?`KX_Z+^S)\'?AUINH
M>(=2DLEFU+Q'=R1V:&[D\N)%$7S'DY9R1M[*W4?8=>5_M(?L?_`#]JG3(]+^
M+W@B&\NH(3'9:Q:2>3>VBDDX25>=N<G:V4)Z@UKB(5G2M2=F)-)W9YA-\+/^
M"I&K7D/B!OVH_AWISQ9>+1[/PA)):RA\;DE=SO?RQ]QE*Y/WNM=-\#W_`."B
M%MXTL]%^/\/PQN?#T+S_`-H:SH<MVM]<#Y_*"0D"-"24SDG@'J37DTO_``3,
M_:/^&MO(G[.'[?WC'3((WADMM+U]WFA,B[0=[(^W9M4`)Y1&!@Y!KSO0/V_O
MVTOV9?VF-._9?_:/M?#_`(YDNM4M+:2^T5%%V8KF1@DB^2%7<-RDQO&I"IQG
M<&/%[3V#3J*2N[;W3;+4>?8_1JBBBO6,SY6_X*Y_`:Y^,?[)5]KVCZ6USJO@
M^[75[94`+M;J"MRHX)V^42Y`QGRAS6I_P2I_:`L?CA^R7HMC>:KYVM>$D71M
M81VR_P"['[B0Y))#1;/F/5E?TP/H^_M+>^M)+2[A62*5"DL;KE74C!!'<&OR
MU\5V/Q'_`."/_P"UTWC30]-;5?AQXQFF$%A;RE5>T#AS`1PJW-ON.PGAD)'&
MYMOEXA_5JZK_`&7H_+L_0TC[T7$_5#(/0T5S/PG^+'@+XU^";+XA_#;Q%:ZI
MI5_'NBN+697V-_%&^"=KJ>&4\@UTU>E&2DKK8S"BBBJ`*0LJ]3BACM4MBODW
M_@H__P`%$-$_9B\(R?#_`.&6JZ??^/\`4,PK;+,)#HT;)G[3*@S\QR`B-C).
M>0I!RK5H4*;G(:3D[(^;OVRM9@_;J_X*5^&/V?O",4EYHGAF\CTS4YXF9HV"
M2>=?2X#J`%0&+<""2N`22M?I]9VR6D"V\2;5C0*@!Z`=*^.O^"3_`.Q-J'P1
M\'3_`!^^*MLY\9^+[;S(X[D2>=I]G(1)LD#\B:1L.Y(R.%SP<_9=<F!I5.65
M2IO)_AT*FTW9=#R#]L;]D'PG^V9\/]/^'/C/Q3J>CVVG:PFHQ7&E"(R.ZQ2Q
M;3YBL-N)2>F>!7>?"3X>6'PD^&>@?"[2K^:ZM?#VC6VGV]S<A?,E2&-8PS;0
M!N(7)P`.:^4?VY_^"A_QL_9V_;M^$_['/PO\*Z5+9_$/P?K.M7^NS^#M5U^[
MLWL2@6.*QTV199%?<<OSMZGBNL_X)Y_\%"KG]K7QG\2_@G\0_#MIHGC;X9Z\
MEG>6)L[O3;C4[*6-9(=0_LV]07-E$X=5`D9PQ#%7X('8J4%/GZD'3?M@?\$\
M/@G^V->6.O\`BV6]T77+#$8UW11&)KB#G$,H=65U!.5)&Y>QP2*Z_P#9%_9=
M\,?LA_";_A4GA'Q)J&JV?]J3WPNM36,2[I=N5_=JJX&T8XS7J!.!FOFW]I?]
MN3Q%\$/V]/V=_P!CC1?`EE>VGQHE\2-JNN7-TXDTZ+2]/%PJQ1J,,SNZ@LQP
M%4X!)!$K#THU?:)>\-MM69](&)2"&P<C'(KYG^*G_!*_]G;QUXN;XD?#Z]US
MX>>(I)"\FI^";_[*KL6#.WE8*@L0<[=H.22">:^FJ\3_`."AG[8B_L%_LF>*
M?VHG^$^L>-/^$<@C8:)H[+'DNZH)9YF!6VMD+!I9R"(T!8@XJJE*%56D@3:V
M.8M?V"?B<+J-M3_;\^,EW;!Q]HMCK-NGFID;EW+%E<C(R.1G/:O5O@#\`-$_
M9Z\.77A3PYXX\4ZS97%SY\:^*=<:_DMV(PPCD=0X4\$J21GICG/SI^TQ^W-^
MUE^R%^SS=_MC_$[X7?#?Q/X'L=/LK[6O#OA+Q/=IJVFP37$,+_99Y8&@U9@)
M0P`6TRP"@MN!KZW\+>([7Q9X?L/$EE:W$$.HV,-W##=PF*9$D0.H=#RC`'!4
M]""*F%"G3=TOS!ML3Q3X7T+QCH-WX8\4:3;W^G7]L]O>V5W$'CFC88*LIX((
MKYKA_P""6O@/P-X@GUC]G7X[?$'X:6MY$!>:5X8UO=;RL-HWXG#L#A1G)/Y<
M5](^-(_%<WAN]@\"ZAI]IK#6S#3KG5;-[BVCE/1I(XY(W=1W"NI]Z^-OV<OV
MR_VX?CA^W3\:OV.M1O/A790?!-_#KZAK<'A34W?68]3M6N66-#J.+=HU0J"3
M("2#@`8+J4*51WDM03:V.YU#_@G-\1/$^C2>'O'/[?7Q>U.RN?EO[0:I#%'<
M1[\[#A"PR``<'GGCG%>O?L]?LI_!#]E_PZWASX.^"+?31.B"^OW)DNKQER0T
MLK?,W)8@?=&>`*]&5MPSCO7F?[:'QNUO]FC]D?XF?M$^&M'M-1U#P+X#U77K
M*POBPAN9;2TDG2-RA#!69`"00<=*F.'I0=T@;;/3:^/_``O_`,$C]!\`^.]6
M^(GPT_:H^(GAK4]8GG>\GT6>VA+++*96C)$7S*&Z9R>!SG).W^QC^U!^T7\>
M=2T.[^)=WI%O!>^'DU'5-.M/@UXDT=$=XU/EP:AJ4HAE"NX_Y9[G12P5>WU*
M#D9IU:%*LTYJ]M@3:V/FD_L%?%;M_P`%#_C-_P"#6V_^-5[_`."O#5SX0\+:
M=X;GUV]U62PLHX)-1U.<R7%TRJ`99&/5F.2>W/&!7D?[?_[;&@_L+?!W3OB7
MK'@RXUFXUSQ18>']*66X^QZ=:W5W,L23ZA?,K1V%JI.6F<'G:JJS,!73_!B_
M_:7U#5[C4_CEJ_P[BL+N*1M,T;P:M[<2P`2?(SWMPZ+<#8#G;;189L#(7EPH
MPIN\0O<],KP#X&?L`^!/@3^TCXH_:6T'QQK5]J?BG[=]JTZ]2#[/#]JN4N&V
M%$#\%`HR3P>:]_KY^_;T_;*UW]CFY^$=UI7P^N_$=IX_^*UKX5UBVTO3+B]O
MK>UFL;RX,]M!;Y>616MD)4*WR;R%)`ISI0G).2VU0)M;'T#17QOXJ_X*@ZJ/
M^"COP-_8N\$?"O5X-$^*&B^)+O7-8\9^#M6T6\M)-.M%GB6U6\AA68.20Y`;
M:-O(R,_9%:"."_:5^`NB_M+?!C6/@MXCUV[TVRUD0B>]L%0S1B.9)1MW@KR4
M`Y!ZU7_9=_9YT']EKX.:9\%_"^NWNIV6F37,D5[J(02N9IGE(.Q0O!<@8'05
MZ+167L::J<]M;6`*\E_;`_9,\+?MC?#>T^&'C'Q-J.D6EIK$6HI<:6L9D9TC
ME0*?,5AMQ*3TSP*]:KYG_8U_;=\;?M)?MB?M+_LV>)/!VE:?IWP/\5:)I6B:
MA8O(9]1CO;!KEWG#,54JR[1L`&.O/-5.$:D7&6P'KW[-_P`"]%_9L^#6B_!;
MP[K5WJ%EH<<J07E\$$LHDF>4[M@"Y!<C@#@5UGB'PUH?BS1+OPUXETJVO]/O
MK=X+VRNX%DBGC889&5L@@CL:O5\K_MO_`+;'[0?[./[1GPV^$'P,^`5C\08?
M$OA;Q'X@\0Z+'?M!JT]II9L`T.FDGR7N"+TN(YMJR>5L#*S`T*G%14>B`2Y_
MX)4?#+POX\N?'G[/?QB\;_#&2]C*WECX2U55MWSZ+*K%5ZX7.%S\N.E:3?\`
M!/#Q%KW_`!+_`(B?MM_&/7=+89DTY_$B6VYQRK>9#&&&#SC/-<S^S)_P5!M?
MVK_VY4_9Z^&?@`Q>!I?@J/&$?B/5(YK?4EU5-3CLKG2I[5POV:6W#KYJ/EPS
M+_"06^O:Q^J4%LBN:1S_`,-_`%K\,O`VF>`M-UO5-1M]*MA!!>ZU?FYNI4!.
M/,E89<@<9/8"O'OC;_P3Y\#?&OQSJOQ*NOC)\1M#UO5(HHQ-H?BN2&WMA$N(
MPD`&W:"6;:<C+L>]'[;?[<L7[)?B?X6?#G2_`D6L>(/BYXU/AOPY<ZOJ;:?I
M%E,L+3,]Y=K#,8BP4)$BQLTCG`P`2/0/@A<?'YM,EG_:!\0^"+F]NHHI+.T\
M&6-U'';<-YB-+<3.UP`2H601PYP24&0!I*C3E'E:T$FUL>1#]@?XW_VJSK_P
M44^+GV'[,%6'[;!YOG;L[M^S:4VX&W;G/.[M6Y\!_P#@F]^S[\#?'+_%F:+5
M/%GB^5Q/+XC\67:W4RW.27N(UVA8Y&)Y8#(P`"!G/T%45Q>06SHDLJJ7.$#,
M,L?0#O4+"T8N]OOU'S2):***Z"0(!ZBN.^.'P,^&_P"T3\.[[X8?%+P['?Z5
M?*"1G;+!*/N31/UCD4\AA].02#V-%3*,9Q:DKH#\Q/$'[/'[='_!,KXA:CXX
M_9C:\\6_#^:X,UQIPC-RK1@8Q=VT>&$BCY1/%Q@9.!A:]F^"/_!;']G#QGI=
MM:_&/2M4\'ZJ6*73+:O>68(0G>'B&\`D8VE,@D#G[U?:30(WKP<UX_\`%C]@
M?]D7XTYF\<_!+1C<F3>U]I<)L9V8L6;=);E&;)))SG.>:\_ZI7P[OAY:=GLO
M0MSC+<F7]O7]C)E#C]I_P4`PR,Z_"/YFN?\`B+_P4R_8E^'&CC5[GX[:3JS-
MGRK/PZYOIG(QQMBR%Z]7*@XX.>*\W;_@A_\`L=,Q8:]XX7)Z+KD.![?\>];'
M@K_@C3^Q3X1U3^U-1T+7_$&'1X[;7=;+1(5;/W85C#@]"K[@1VH<\R>G+%?-
MBM3[GAOQ<_X*Z?&GX[>+5^#W[#/PJO1=WLOE6^K7MH)[V3+!=\</,4"C/WY2
M0,Y(6N]_8?\`^"5\W@SQ3%^T/^UAJG_"0>-GNY+R+29YQ<P6L[-N6XF<C]_.
M#D_W%)&,E01];_#/X(?"7X,Z4=%^%/P[T?P_;,`)$TJP2(R`$D;V`W/@L<;B
M<5U*1JF=O>G2P4I252O+F?X+T\PYK;"H"%&[KCFEHHKT23SCXR_LE_L]?'_Q
M+HOC7XM_"O3=7UOP[#/#H6MDR07MA'.`LT<5Q"R2*C@`,N[:<=*W_AE\%_A/
M\&]/N-*^%/PST#PU;W4WG7<6A:1#:BXEVA?,D\M1YCD*H+-DG`YX%=110`5R
MOB_X+?"GQUX\\+_%+Q?\/M)U'Q)X+GN9O"FN75DK7.E/<0F"<PR?>021L58`
MX(QGH,=510`V/=L`88-4_$GAK0/&.@WGA;Q7HEGJ6F:A;/;ZAIVH6J3P7,+J
M5>.2-P5=&4D%2""#S5ZB@#RS2/V(_P!D7P]JUOK>B_LS^!89[*>.?3B/"]J4
MT^5"&#VR%"ELVX!R8@A9@&.6&:]3HHH`"`>HKD_#7P1^%7A'XF>(OC+X:^'^
MDZ?XJ\6VUI!XFUZTLU2YU-+576W$S#[_`):R.JD\@''0`5UE%`!6-\0_A]X.
M^*W@?5_AK\0_#UKJ^@Z]IL^GZSI5]%OAO+69"DL3KW5D)4CT)K9HH`\$^!__
M``3$_8)_9L^(=E\6/@3^ROX3\,>(]-CECL=7TNT9)H5DC,;A26(`*,R_0U[W
M110!G>+?"'A3Q]X<O/!_CCPUI^LZ3J$!AO\`2]5LH[BWN8SU22.0%77@<$$5
MP_PM_9'_`&:_@GXB?Q-\)O@;X9T"^9IC%=:9I,<36JRG,L<&!_H\;M\S1Q;$
M9B6*DDFO2:*`"N=\;?"GX??$K4_#^L>/?"-CJESX4UQ=8\.37D6YM/OEBDA6
MXCY^5Q'-*N?1S7144`<GK_P0^%'B?XI:%\;=?^'VDWOBWPSI]Y8^'O$-U:*]
MUIUO=;/M$<+GF,2>6@;')`QT)%=6N=HR,&EHH`****`"N5\#_!7X6?#/Q5XG
M\<^`/`.E:5K/C74XM0\6ZI8V:QSZK<QPK"DL[CF0K&BJ,\`9QR23U5%`!7.:
MS\)OAYK_`,1M%^+>L>#[*Y\2^';"[LM$UJ6+,]G!=&(W$:-V63R(=WKY:UT=
M%`'":%^S3\"?#GQQU7]I;0_A1H=GX^US1TTK6/%EM8JE[>V:LCK#+(,;P#&G
M)Y^11G"@#NZ**`,+XC?#+X=?%OPT_@SXI>`-%\2Z1+,DLFEZ_I4-[;,Z'<CF
M*960LIY!(X/(KEOA7^RA^SO\#M8EU_X0_!7PWX>O)A,IN=-TM$DB2:3S)(8F
MQF"%I/G,,>V/<2VW))KT:B@`KEO&OP9^%GQ%\5^'_''CGX<:)K&L>$[F2Y\,
MZIJ>FQSSZ7-(`'D@=P3$QVKRN#\H]!74T4`%%%%`!1110`4444GL`4444=0"
MBBBA;`%%%%,`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
BHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`/_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
